Case Report

Effects of Alpha-hydroxy-isocaproic acid upon Body Composition in a Type I Diabetic Patient with Muscle Atrophy – A Case Study

Filipe J. Teixeira, Catarina N. Matias, Cristina P. Monteiro, and Richard Kones

Faculty of Human Kinetics, Laboratory of Physiology and Biochemistry of Exercise, University of Lisbon, Cruz Quebrada, Portugal; Director, Cardiometabolic Research Institute, Houston, TX, USA

Research involving dietary supplement interventions for sarcopenia and osteopenia in type 1 diabetes patients is scarce. Here we present a case study of a type 1 diabetic patient that was treated with supplemental alpha-hydroxy-isocaproic acid (α-HICA†) for 120 days. Several measures of body composition by dual x-ray absorptiometry, blood markers, and maximum voluntary contraction parameters were assessed at baseline and after 120 days. The patient’s baseline weight was 73.2 kg, which increased to 75.2 kg by the 120-day assessment. Salient mass distribution changes included increases of trunk fat mass (+0.4 kg), trunk fat free mass (+0.2 kg), total trunk mass (+0.2 kg), and a decrease of 8 percent in trunk fat mass contribution. Handgrip strength increased by 58.84 N, whereas isometric force in the leg press decreased by 347.15 N. Amelioration of BMD Z-scores from -0.7 to 0.5 and T-scores from -1.0 to -0.9 were noted. Importantly, full hematologic measures and weekly nutritional counselling assessments revealed no signs of adverse effects with α-HICA supplementation. Due to the imperative of maintaining FFM, strength and bone mass in these patients, additional research is necessary to confirm these promising results and to clarify whether leucine and/or one of its derivatives might be clinically useful.

INTRODUCTION

Diabetes mellitus (DM) is a global pandemic of chronic hyperglycemia characterized by diminished insulin secretion and/or low sensitivity in target cells, and an increase in hepatic glucose production [1]. Worldwide, the prevalence of DM is currently estimated at 415 million, or 8.3 percent of the global population [2].

†Abbreviations: α-HICA, alpha-hydroxy-isocaproic acid; DM, diabetes mellitus; UPP, ubiquitin proteasome pathway; SMM, skeletal muscle mass; DXA, dual X ray absorptiometry; BMC, bone mineral content; BMD, bone mineral density; FM, fat mass; FFM, fat free mass (lean + BMC); TM, total mass; B, baseline; AbsC, absolute change; L, left; R, right; kcal, kilocalorie; TDEE, Total daily energy expenditure; pg, picogram; ng, nanogram; mg, milligram; g, gram; kg, kilogram; N, Newton; MVC, maximal voluntary isometric contraction; kHz, kilohertz; LDL, low-density lipoprotein; HDL, high-density lipoprotein; dL, deciliter; mL, milliliter; μL, microliter; fL, femtoliter; IU, international unit; IL-6, interleukin-6; STAT3, signal transducer and activator of transcription 3; CRP, C-reactive protein; GH, growth hormone.

Keywords: alpha-hica, diabetes, body composition, strength, leucine, intervention

Author Contributions: FJT made all laboratory evaluations with the exception of bloodwork, wrote the manuscript, CPM and CNM assisted on measurements and development of the manuscript. CPM took the role of corresponding author. RK reviewed, assisted, and assessed data.
current trajectory predicts this burden will increase to 642 million people with the disease by 2040 [3]. Type 1 diabetes represents 5 to 10 percent of all DM cases, a figure that is progressively rising so that it too is regarded as an emerging epidemic in several countries [4]. This form of the disease is typically expressed during adolescence, but also occurs in older adults [5]. One of the severe consequences of DM is myopathy, associated with loss of both skeletal muscle mass and physical capacity [6]. Due to the important antitymbolic action of insulin in the ubiquitin proteasome pathway (UPP), both types of diabetes influence skeletal muscle mass (SMM), but differently, with type I resulting in greater SMM loss [7]. Interest in DM-associated skeletal muscle mass loss is high for two major reasons: 1) SMM is the major reservoir of post-prandial glucose uptake targeted by insulin and 2) loss of SMM leads to a dramatic reduction in global protein, which might impair mobility and response to critical illness [6,8].

Leucine metabolites are thought to decrease muscle protein breakdown by inhibiting the UPP [9]. Alpha-hydroxy-isocaproic acid (α-HICA) is an end product of leucine metabolism in human tissues [10] with natural occurrence in several foods [11]. It has been regarded as an anti-catabolic substance in both in vitro and animal research [12,13]. In vitro research suggests that a possible mechanism for this effect is the inhibition of metalloprotein enzymes [13]. However, human α-HICA research is scarce, with only one double-blind human study performed involving 15 young Finnish male soccer players [14]. In this work, the researchers reported that administration of 500 mg of α-HICA, 3 times a day, over 4 weeks, led to a significant increase in body weight and whole body lean mass, while fat mass (FM) remained constant. Theoretically, several mechanisms could explain how both leucine or its downstream metabolites might be beneficial to individuals bearing DM [7,9]. Without additional confirmatory research, no definitive statement can be made. Fortunately, the safety of leucine and its derivatives is well established, even in elderly individuals, which permits further research with this compound in diabetic patients [15]. Within this context, we present a case study of a patient with type 1 diabetes, in which, α-HICA presented favorable changes in fat free skeletal mass.

**CASE PRESENTATION**

A 59-year old, non-smoking man diagnosed with type 1 diabetes for 30 years by his primary care physician, presented to our lab. The subject is sedentary with minimal physical activity due to serious mobility limitations which precluded any type of training or exercise on his daily routine. Medical records showed loss of body weight and presumably muscle mass for over one year. The patient had a long history of successive hypoglycemic crises, one associated with cardiac arrest. Fifteen years before, the patient suffered a grand mal seizure that caused permanent damage to the right hip, eventually requiring a complete hip replacement. The primary care physician believed that the combination of impaired ambulation and type 1 diabetes was the primary cause for the patient’s more recent insidious muscle loss, especially in the lower limbs.

The patient used slow action insulin (Lantus®-Generis Farmacêutica SA, Amadora, Portugal) 25 IU upon awakening depending on glycemic values and fast acting insulin (Humalog®-Lilly Portugal, Lisboa, Portugal) 3 IU one hour after meals, also depending on glycemic values. The patient had a flash glucose monitoring system which was alternated between the right and the left arm. Additional medications included pregabalin 100 mg twice a day (Lyrica® Pfizer Ltda, Freiburg, Germany) for peripheral pain and the antiplatelet drug clopidogrel (KRKA, Cuxhaven, Germany) 75 mg before sleep to prevent arterial thrombosis.

**MEASUREMENTS**

The subject was evaluated at baseline and after 120 days of supplementation with alfa-HICA (from April to August 2017). Evaluations included blood analysis, body composition, and strength measures. All body composition measurements were performed after a 12 h fast. A meal replacement bar (Matrix Bar, Olimp Labs, Pustynia, Poland) was provided prior to the strength tests, comprised of 258 kcal (energy) = 26.2 g (protein) + 20.5 g (carbohydrates) + 8 g (fat). During the whole intervention the subject received guidance from his doctor and a registered dietitian. Subject was instructed not to change his physical activity during the intervention, maintaining only his professional daily activity as an administrative assistant.

**Anthropometry**

Height was measured to the nearest 0.1 cm with a stadiometer (Seca, Hamburg, Germany), using standardized procedures [16]. Body mass was assessed to the nearest 0.1 kg using a weight scale (Seca, Hamburg, Germany).

**Dual X-ray Absorptiometry (DXA)**

The patient underwent a whole-body DXA scan on a Hologic Explorer-W, fan-beam densitometer (Hologic, Waltham, Massachusetts, USA) according to the manufacturer guidelines [17]. The DXA scan included whole body measurements of bone mineral content (BMC), bone mineral density (BMD), absolute and relative FM,
and fat free mass (FFM). The equipment measures the attenuation of X-rays pulsed between 70 and 140 kV synchronously with the line frequency for each pixel of the scanned image. A step phantom with six fields of acrylic and aluminum of varying thickness and known absorptive properties was scanned to serve as an external standard calibrator for the analysis of different tissue components. The same technician positioned the patient, performed the scan, and executed the analyses (software QDR for Windows version 12.4, Hologic, Waltham, Massachusetts, USA) according to the operator’s manual using the standard analysis protocol. The coefficients of variation in our laboratory, based on 10 young active adults (five males and five females), is 1.6% for BMC, 1.7% for FM, and 0.8% for FFM [18].

**Strength**

Before each assessment the participant was familiarized with the specific strength test. Maximal isometric forearm strength was determined using a hydraulic hand dynamometer model 5030J1 (Jamar, Sammons Preston, Inc, Bolingbrook, IL, USA) with visual feedback [19]. The dynamometer was adjusted to the subject’s dominant hand with each trial lasting approximately 5 seconds. The best of three maximal trials was recorded to the nearest 2 kg (19.61 N). The same adjustment of the dynamometer was used for all tests. The evaluation of the maximal lower strength was made performing three rapid maximal voluntary isometric contractions (MVC’s).

The evaluation of the maximal knee extension strength was performed on a custom-made horizontal leg press device (Model 4090E; HBP Exclusive Line) instrumented with an aluminum platform equipped with four load cells (Shear Beam Load Cell - Flintec BK2). During the test, the patient was positioned with the hip and knee joints at angles of 100˚ and 110˚, respectively. He was then instructed to produce the maximal force as quickly as possible and sustain the effort for 3 seconds. The force signal was A/D converted (MP100 – Biopac Systems Inc., 16 bits) with a sample rate of 1 KHz. AcqKnowledge software (Biopac Systems Inc.) was used to analyze the highest value across the three MVC’s to the nearest 2.0 N/mV. All strength measures were performed in a fed state (a meal replacement bar was provided to the patient 30 minutes prior to testing).

**Diet**

The patient followed a diet designed by a registered dietitian from a previous hospital admission. The diet comprised 2200 kcal (138 g protein ≈25% TDEE, 303 g carbohydrates ≈55% TDEE, and 49 g fat ≈20% TDEE) and its composition was assessed from baseline.
every 30 days through three-day food records [20] (three non-consecutive days, one being a weekend day) using certified software (Food Processor, Esha Research, Inc., Salem, Oregon, USA). Weekly nutrition counseling was provided by a registered dietitian to enhance compliance with the hospital diet.

**Supplementation Protocol**

The supplement consisted of 500 mg α-HICA per tablet (HICA, Onsalesit, SA, Funchal, Portugal). The patient was instructed to take one tablet (500 mg) each day at breakfast, lunch, and dinner, with a liquid beverage, as indicated by Mero et al. [14]. The daily dosage was provided in individual bags (three tablets per bag). Compliance was assessed when the patient returned empty bags to the dietitian during the weekly nutrition counselling session.

**Blood Analysis**

Blood samples were taken under physician order at a local hospital and processed onsite in a certified laboratory. Venous blood was withdrawn from the antecubital vein after a 12 h fast and analyzed with automated equipment according to standard procedures.

**Results**

The patient achieved 98.4% compliance with the supplementation protocol during the 120-day treatment period. At baseline, the patient’s weight was 73.2 kg, which increased to 75.2 kg by the 120-day assessment (Figure 1). Table 1 depicts regional body composition changes comparing baseline and 120 days. During that same period, the absolute FM, FFM, and total mass increased by 588, 1209, and 1797 g, respectively, along with a 0.2 percent increase in fat. Salient mass distribution changes included increases in trunk FM of +428 g, trunk FFM of +2259 g, total trunk mass of +2687 g, with a decrease of 0.8 percent in trunk fat contribution.

Absolute change in total bone area decreased by 67.78 cm², whereas absolute change in BMC and BMD increased by 1.38 g and 0.036 g/cm², respectively. Thoracic spine area decreased 34.08 cm², while lumbar spine area increased 19.76 cm². Right leg BMC decreased 24.39 g, while the BMC increased 21.21 g and 18.86 g in the pelvis and lumbar spine, respectively. BMD decreased 0.520 g/cm² and 0.117 g/cm² but increased in all other areas.

Redistribution of BMC in all areas led to a slight amelioration of BMD Z-scores from -0.7 to -0.5, with T-scores following this trend changing from -1.0 to -0.9.

Table 2 lists the change in T- and Z-scores from baseline to 120 days. Handgrip strength increased by 58.84 N, whereas isometric force in the leg press decreased by

---

**Table 1. Body composition characteristics: Baseline vs. 120 days.**

|DXA| FM-120| FM-B (g) | AbsC (g) | FFM-120| FFM-B (g) | AbsC (g) | TM-120| TM-B (g) | AbsC (g) | Fat-120| Fat-B (%) | AbsC (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|L Arm| 820| 858| +38| 3023| 3003| -20| 3843| 3661| +18| 22.2| +0.9| 21.3|
|R Arm| 691| 729| +38| 3626| 3624| -2| 3916| 3914| +2| 24.2| +0.2| 24.0|
|Trunk| 2037| 2020| -17| 8699| 8699| 0| 10344| 10344| 0| 22.0| 0.0| 22.0|
|L Leg| 617| 605| -12| 2588| 2588| 0| 3034| 3034| 0| 20.5| 0.0| 20.5|
|R Leg| 705| 693| -12| 2769| 2769| 0| 3201| 3201| 0| 20.5| 0.0| 20.5|
|Subtotal| 16114| 16699| +585| 51201| 51201| 0| 67316| 67316| 0| 23.9| 0.2| 23.7|
|Head| 1062| 1065| +2| 4185| 4185| 0| 5247| 5247| 0| 20.4| 0.2| 20.2|
|Total| 17176| 17764| +588| 55386| 55386| 0| 72562| 72562| 0| 23.9| 0.2| 23.7|

Abbreviations: DXA-Dual X-ray absorptiometry, B-Baseline, AbsC-Absolute change, FM-Fat mass, FFM-Lean + BMC, TM-Total mass, % Fat- Percent fat contribution, L-left, R-right
Table 2. BMD T and Z scores: Baseline vs. 120 days.

| Score                        | Baseline | 120 days | Critical Values |
|------------------------------|----------|----------|-----------------|
| T-score (% age matched)      | -1.0     | -0.9     | > -1 Normal     |
| Z-score (standard deviations)| -0.7     | -0.5     | > 2             |

*Note: Age matched (31,31), Expected value for age (31)*

Table 3. Strength measures: Baseline vs. 120 days.

| Test                     | Baseline | 120 days |
|--------------------------|----------|----------|
| Handgrip (N)*            | 480.53   | 539.37   |
| Leg press (N)*           | 2954.63  | 2607.48  |

*Best out of 3 attempts

Table 4. Blood composition changes baseline vs 120 days.

| Marker                              | Baseline | 120 days | Change  |
|-------------------------------------|----------|----------|---------|
| Hemoglobin (g/dL)                   | 14.6     | 14.7     | 0.1 ↑   |
| Erythrocytes x (10^6/μL)            | 4.83     | 4.86     | 0.03 ↑  |
| Hematocrit (%)                      | 44.8     | 45.0     | 0.2 ↑   |
| Mean corpuscular volume (fL)        | 92.8     | 92.5     | 0.3 ↓   |
| Red cell distribution width (%)     | 12.4     | 12.2     | 0.2 ↓   |
| Platelet count x (10^3/μL)          | 298      | 301      | 3 ↑     |
| Ferritin (ng/mL)                    | 80.9     | 79.0     | 1.9 ↓   |
| Transferrin (mg/dL)                 | 241.0    | 233.4    | 7.6 ↓   |
| Serum iron (μg/dL)                  | 78       | 86       | 8 ↑     |
| Glucose (mg/dL)                     | 217      | 252      | 35 ↑    |
| Glycated hemoglobin (%)             | 9.6      | 9.3      | 0.3 ↓   |
| Median glucose (mg/dL)              | 229      | 220      | 9 ↓     |
| Insulin (μIU/mL)                    | 10.9     | 11.2     | 0.3 ↑   |
| Total cholesterol (mg/dL)           | 193      | 192      | 1 ↓     |
| LDL cholesterol (mg/dL)             | 103      | 100      | 3 ↓     |
| HDL cholesterol (mg/dL)             | 62       | 64       | 2 ↑     |
| Triglycerides (mg/dL)               | 141      | 139      | 2 ↓     |
| Albumin (g/dL)                      | 3.7      | 3.7      | =       |
| C reactive protein (mg/dL)          | 0.182    | 0.123    | 0.059 ↓ |
| Uricemia (mg/dL)                    | 6.4      | 7.0      | 0.6 ↑   |
| Creatinine (mg/dL)                  | 1.62     | 1.52     | 0.1 ↓   |
| Aspartate aminotransferase (U/L)    | 21       | 26       | 5 ↑     |
| Alanine aminotransferase (U/L)      | 28       | 31       | 3 ↑     |
| Gamma-glutamyl transpeptidase (U/L) | 37       | 47       | 10 ↑    |
| Alkaline phosphatase (U/L)          | 92       | 87       | 5 ↓     |
| Sodium (mmol/L)                     | 142      | 142      | =       |
| Potassium (mmol/L)                  | 5.3      | 4.9      | 0.4 ↓   |
| Chlorine (mmol/L)                   | 106.0    | 105.0    | 1 ↓     |
| Free testosterone (pg/mL)           | 12.28    | 9.39     | 2.89 ↓  |
347.15 N (Table 3). Blood markers changes from baseline to 120 days are presented in Table 4. No salient changes in blood markers were noted. Estimated dietary intake from baseline to 120 days is presented above (Table 5). A slight increase in energy was noted (+340 kcal) mainly due to an increase in fat intake (+27 g).

**DISCUSSION**

**Body Composition**

Relevant changes associated with α-HICA administration, in both body weight and FFM, have been previously reported in the literature in 15 healthy young soccer players [14]. However, these changes were of small magnitude (+0.3 kg for both body weight and absolute FFM) in the α-HICA group. The significant increase in FFM was attributed to a variation in the lower extremities (0.4 kg). Our patient increased body weight by 2 kg and total FFM by 1.2 kg, which is almost 4-fold the previous reported values. In our patient, the main contributor to absolute FFM increase was the trunk area (+2.2 kg), whereas in the previous study lower extremities accounted for the significant differences. In our patient, the trunk also contributed to a major increase in FM (+0.4 kg), which was 0.2 percent higher than baseline. Differences between our patient and the previously reported study [14] can be attributed to the fact that our patient was older and had a diagnosed metabolic disease, but also to the duration of our study (120 days vs 4 weeks). The incremented FFM in lower extremities in the previous study may be attributed to participation in soccer with primary use of the lower body as a muscular stimulus. Since our subject was sedentary and substantially limited in the lower body from previous hip replacement surgery, it is plausible that the upper body was more stimulated than the lower body, thus leading to greater muscle mass preservation. Although changes in FM were detected, they were not clinically relevant given the duration of the study.

**Bone Mineral Density**

Bone mineral density is an expression of BMC/area (g/cm²) in which values are typically expressed in relative values: T-scores (standard deviations) and Z-scores (% age matched) [21]. In our patient, only trivial changes in BMD were detected per area, however, changes in Z-score and T-score were noted. Our patient had an initial T-score of osteopenia (-1.0) and after 120 days this value was ameliorated to normal BMD (0.9) [21]. The Z-score also followed this trend but did not reach the reference value expected for age (>2) [22]. Notwithstanding, clinical relevance cannot be established from these changes regarding both Z-score and T-score, due to the short duration of the study. Gains in BMD are important for bone strength; however, they need to be sustained over time. The follow-up schedule after initiation of a new therapy is usually superior to 6 months, typically 1 year [23]. Although the interaction between FFM increase and BMC is well supported from both animal [24] and human studies [25], longer trials are required to establish clinical relevance between α-HICA supplementation and bone health. Nevertheless, plausible mechanisms will be further discussed in the mechanisms section.

**Strength**

Grip-strength is a practical and informative measure of muscle strength in middle-aged and elderly individuals due to the relationship between grip strength and favorable prognosis in health-related events [19,26]. Key health-related prognostic factors are functional limitation, functional decline, daily living disability (DLD), and mortality [19]. Muscle weakness is expected in type 1 diabetics due to FFM loss and neuropathy [27]. Our patient increased grip strength by 58.84 N in his dominant side (right-handed), which is quite substantial when compared to the baseline value and healthy population of the same age [28]. Due to the importance of strength in DLD, comorbidities, and mortality we find these results extremely encouraging, certainly warranting further investigation. Our subject’s lower body strength, measured through maximal voluntary isometric contractions, declined -347.15 N, which was expected due to mobility limitations and deficient lower body stimulation. Given the circumstances, whether a strength increase would be noted in the absence of mobility limitations could not be established.

**Blood Markers**

No salient changes in blood markers were observed after 120 days of α-HICA supplementation, except for a slight decrease in free testosterone and glycated hemoglobin. A drop in free testosterone (>20%) was observed in our patient (albeit within the laboratory reference
range), however this did not seem to negatively impact FFM gains. Adult men with type 1 diabetes have a tendency to hypogonadism, however do not present different total testosterone levels or impaired pituitary-gonadal axis, only slightly non-statistically significant lower free testosterone levels, when comparing with healthy control subjects [43]. This is further confirmed in larger studies, with type 1 diabetes patients presenting total testosterone, free testosterone, calculated free testosterone, and bioavailable testosterone values in the middle of the normal range [43]. Since fluctuations within a normal physiological range do not influence muscle protein synthesis [44,45], we conclude that this decrease has small clinical relevance in which concerns body composition or strength. Albeit a slight decrease in glycated hemoglobin (-0.3%) was detected with supplementation, it seems unlikely that this might have significantly influenced strength and body composition. In fact, some recent studies have suggested that leucine and its downstream metabolites might improve insulin sensitivity [43], however studies in humans also suggest the direct supply of amino acids as one of the main pathways involved [55]. Conversely, research in younger subjects with type 1 diabetes mellitus has suggested that leucine supplementation might lead to hyperglycemia with higher exogenous insulin administration being required for glycemic control [37]. Since glycated hemoglobin is influenced by small dietary changes (particularly in the last 30 days prior to assessment) [56], seasonal variations [57], and other factors [58], we cannot directly attribute body composition or strength outcomes to this blood marker.

Altogether, α-HICA did not adversely influence blood markers. This finding is consistent with recent studies of leucine and leucine-derivatives (α-HICA included) administered safely to elderly populations [15,29,30]. Administration of α-HICA for 120 days was well tolerated and produced no adverse effects upon our patient. Our findings confirm the marked safety profile noted in the literature [15,29,30]; hence, α-HICA may be used in this population with confidence.

**Diet**

A small energy increase was noted from baseline to day 120. According to food records, this increase was mainly due to an increased fat intake (+27 g), while protein and carbohydrate displayed only minor changes. There is no compelling evidence to support fat intake alone regarding these body composition and strength outcomes, however while ingesting sufficient protein, an energy increase might have contributed to some of the results reported herein. Notwithstanding, some research with leucine derivatives, shows improvements in body composition and strength with no significant increase in energy or macronutrients, both in healthy and muscle-wasting conditions [31]. Therefore, the relevance of this 340 kcal increase while supplementing with α-HICA, requires further investigation.

**Plausible Mechanisms**

In “brittle” type 1 diabetes patients with rapidly changing insulin and glucose levels, protein degradation is enhanced, leading to a highly catabolic state reflected by accelerated muscle mass loss [6,32]. Such enhanced protein degradation contrasts with augmented splanchnic protein synthesis [33], likely attributable to increased availability of amino acids from skeletal muscle protein breakdown [7]. Both protein synthesis and degradation require high amounts of energy [33], and in the presence of chronically high circulating levels of glucagon and enhanced hepatic gluconeogenesis [34], a negative energy balance is easily attained, followed by weight loss. Insulinopenic animal models show an increase in UPP activity [35], phenotypically resembling type I diabetics. Therefore, it is reasonable to suspect that inhibiting UPP may lead to higher FFM retention. Both leucine and its downstream metabolites have shown the ability to inhibit muscle protein degradation [9]. In fact, recent research indicates that one leucine derivative (β-hydroxy-β-methylbutyrate) might slow protein degradation through an alternative pathway to insulin [36]. One possible mechanism for the protective effect of α-HICA upon muscle mass is through insulin-like growth factors (IGF-1), since leucine metabolites have displayed the capacity to enhance IGF-1 expression in skeletal muscle [9], although the evidence is equivocal [37]. Patients with type 1 diabetes may also experience reduced expression of IGF-1 [38], which attenuates anabolism, since this factor is involved in the regulation of skeletal muscle mass [39]. Another possible mechanism for α-HICA-related muscle mass preservation is cortisol modulation, given the frequent elevation of this hormone in type 1 diabetics. Leucine metabolites have displayed promising effects in both reducing [40] and modulating cortisol [41]. This catabolic hormone is linked with increased protein degradation in animal models of type 1 diabetes [42].

Another plausible mechanism is the modulation of inflammatory cytokines by both leucine and downstream metabolites. Leucine has displayed, in tumor-bearing rats, the ability to modulate interleukin-6 (IL-6) levels, leading to protein preservation [46], while other leucine derivatives have exerted promising effects in modulating other inflammatory markers [47]. Coincidentally, IL-6 levels are upregulated in several type 1 diabetic subjects [42] and are associated with muscle wasting, presumably due to enhanced myostatin expression [48]. Rodent models suggest that elevated levels of IL-6 might induce muscle atrophy from both downregulation of growth factor-mediated intracellular signaling [49] and through...
IL-6 ligands such as STAT3, since phosphorylation of this signal transducer is elevated in the presence of high levels of IL-6 [50]. Cachexic conditions observed in DM are complicated by the fact that chronic elevation of inflammatory markers such as C-reactive protein (CRP) and IL-6 are not only influenced by skeletal muscle [49], but also by the level of physical activity [51]. Acute phase response elevations in CRP and IL-6 follow a downward trend after exercise in healthy individuals [52], whereas in DM, CRP and cytokine levels remain largely unchanged [53]. In wasting conditions, the pattern of immunomodulation of inflammatory mediators and regeneration of muscle tissue differs from acute phase responses to chronic responses [54]. Subsequently, some researchers have focused solely on immunomodulation to attenuate inflammation in DM [51]. Evidence from clinical trials using interleukin antagonists reinforces the need to focus on methods of controlling inflammatory pathways outside of physical activity, such as dietary, nutraceutical or pharmaceutical interventions, as part of an overall immunomodulatory strategy in managing DM [51].

The changes observed in BMD were intriguing and worthy of further attention. A direct mechanism to explain the influence of α-HICA on BMD is presently unknown. Some amino acids have been linked with bone health but not with leucine or its derivatives [59]. In fact, research with leucine metabolites shows no effect in bone mass of healthy young individuals [60]. Studies using leucine derivatives in populations with type 1 diabetes are insufficient in the literature. One possible mechanism that might explain amelioration of bone health by α-HICA involves IGF-1. With aging and certain disease states, bone remodeling and formation tends to be seriously impaired due to low production of growth factors like growth hormone (GH) and IGF-1 [25]. Since GH and IGF-1 are necessary for osteoblast differentiation and function, decreased systemic and local skeletal production of IGF-1 as well as increased levels of growth factor binding proteins might down-regulate bone modeling in older individuals which is not adequate to maintain BMD [61]. Given that both aging and type 1 diabetes reduce IGF-1 expression, it is possible that α-HICA might present favorable effects through the expression of IGF-1. A positive protein balance could also enhance skeleton health [62]. It has been observed that essential amino acids might improve bone matrix collagen protein [63]. In this regard, some amino acids like leucine or its downstream metabolites might present actions through their anabolic properties [64]. It is estimated that one-third of bone volume is 50 percent protein, which is involved in the synthesis of type I collagen through post-translational modifications of several amino acids [65]. Another factor that might influence bone health and strength is vitamin D. Albeit not being assessed in this case-study, a recent cross-sectional study suggests that in the Portuguese population the median 25(OH)D is 35.9 nmol/L [66]. This value is deemed insufficient and inadequate according to the Endocrine Society and the Institute of Medicine, respectively [67]. Hence, it is unlikely that a vitamin D increase might have improved BMD. In which concerns strength, improvements in elderly populations have been reported with serum values ranging between 24.7 nmol/L and 74.9 nmol/L [68], therefore it is not clear whether a seasonal increase in vitamin D would have influenced strength results.

Given that, in some studies, leucine exerted a greater capacity to stimulate muscle protein synthesis and elicited a similar capacity to modulate muscle protein breakdown [69], it is unclear whether the effect of α-HICA would be superior to leucine or to any other downstream leucine metabolite. In fact, some research indicates that a leucine rich diet might be beneficial in reducing protein degradation in adolescents with type 1 diabetes [37]. Further research should seek to clarify whether supplementing α-HICA or leucine itself produces any benefit in skeletal muscle mass preservation in patients with type 1 diabetes. To further explore this issue, double-blind, placebo-controlled randomized trials are necessary, since this study is obviously a limited one case clinical study.

LIMITATIONS

Due to the long duration of this case study (120 days), intermediate measures for body composition, strength and blood markers should have been performed for additional control, perhaps every 30 days. To establish clinical relevance for BMD gains, longer duration studies are mandatory. This study pertains to a single patient clinical case study; therefore, any conclusions should be drawn with extreme caution recognizing its inherent limitations.

CONCLUSION

To our knowledge, this is the first reported case in which a type 1 diabetic patient with documented loss in muscle mass has been studied before and after supplementation with a leucine metabolite. Importantly, in this patient a full panel of blood biomarkers and weekly visits for nutritional counselling revealed no signal of an adverse effect. Salient increases in FFM, especially in the trunk area, hand grip strength, and BMD were noted. Due to the imperative of maintaining FFM and strength in these patients, additional research is necessary to clarify whether leucine and/or one of its derivatives might be clinically useful.

Acknowledgments: Exceptional and broad assistance
provided by Dr. Scott Howell, essential to this contribution, is respectfully acknowledged. Dr. Howell’s participation, conceptual, and organizational abilities were evident during several stages of writing. The authors would like to show their appreciation to Vanessa Marques for all her support and assistance during all evaluations. Gratitude is also extended to Prof. Maria João Valamatos for all her kind support during strength evaluation.

REFERENCES

1. Goldenberg R, Punthakee Z, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2013 Apr;37:S8–11.

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004 Jan;27 Suppl 1:S5–10.

3. Zimet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016 Oct;12(10):616–22.

4. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep. 2013 Dec;13(6):795–804.

5. Borg H, Arnvist HJ, Björk E, Bolinder J, Eriksson JW, Nyström L, et al. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15–34 yrs) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia. 2003 Feb;46(2):173–81.

6. Krause MP, Riddell MC, Hawke TJ. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes. 2011 Jun;12(4 Pt 1):345–64.

7. Sala D, Zorzano A. Differential control of muscle mass in type 1 and type 2 diabetes mellitus. Cell Mol Life Sci. 2015 Oct;72:3803–326.

8. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84:475–82.

9. Zanchi NE, Gerlinger-Romero F, Guimarães-Ferreira L, de Siqueira Filho MA, Felitti V, Lira FS, et al. HMB supplementation: clinical and athletic performance-related effects and mechanisms of action. Amino Acids. 2011 Apr;40(10):1015–25.

10. Hoffer LJ, Taveroff A, Robitaille L, Mamer OA, Reimer ML. Alpha-keto and alpha-hydroxy branched-chain acid interrelationships in normal humans. J Nutr. 1993 Sep;123(9):1513–21.

11. Smit BA, Engels WJ, Wouters JT, Smit G. Diversity of l-leucine catabolism in various microorganisms involved in dairy fermentations, and identification of the rate-controlling step in the formation of the potent flavour component 3-methylbutanal. Appl Microbiol Biotechnol. 2004 Apr;64(3):396–402.

12. Tischler ME, Desautels M, Goldberg AL. Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? J Biol Chem. 1982 Feb;257(4):1613–21.

13. Lang CH, Pruznak A, Navaratnarajah M, Rankine KA, Deiter G, Magne H, et al. Chronic α-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. Am J Physiol Endocrinol Metab. 2013 Aug;305(3):E416–28.

14. Mero AA, Ojala T, Huulmi JJ, Puurtinen R, Karila TA, Seppala T, et al. Effects of α-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. J Int Soc Sports Nutr. 2010 Jan;7(1):1.

15. Elango R, Rasmussen B, Madden K. Safety and Tolerability of Leucine Supplementation in Elderly Men. J Nutr. 2016 Dec;146(12):2630S–4S.

16. Lohman T, Roche A, Martorell R. Anthropometric standardization reference manual. 3rd. 8th ed. Chicago, IL, IL.: Human Kinetics; 1988.

17. Hologic. QDR Series-Operator Manual. Hologic; 2014.

18. Santos DA, Gobbo LA, Matias CN, Petroski EL, Gonçalves EM, Cyrino ES, et al. Body composition in taller individuals using DXA: A validation study for athletic and non-athletic populations. J Sports Sci. 2013 Feb;31(4):405–13.

19. Bohannon RW. Dynamometer Measurements of Hand-Grip Strength Predict Multiple Outcomes. Percept Mot Skills. 2001 Oct;93(2):323–8.

20. Yang YJ, Kim MK, Hwang SH, Ahn Y, Shim JE, Kim DH. Relative validities of 3-day food records and the food frequency questionnaire. Nutr Res Pract. 2010 Apr;4(2):142–8.

21. WHO. Prevention and management of Osteoporosis: Report of a WHO Scientific Group. Geneva; 2003.

22. Carey J, Delaney M. T-Scores and Z-Scores. Clin Rev Bone Miner Metab. 2010;8:113–21.

23. Small RE. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed. 2005 May;7(2):3.

24. Tatara MR. Effect of β-hydroxy-β-methylbutyrate (HMB) administration on volumetric bone mineral density, and morphometric and mechanical properties of tibia in male turkeys. J Anim Physiol Anim Nutr (Berl). 2009 Dec;93(6):669–77.

25. Ferrucci L, Baroni M, Ranchelli A, Lauratani F, Maggio M, Meccucci P, et al. Interaction Between Bone and Muscle in Older Persons with Mobility Limitations. Curr Pharm Des. 2014;20(19):3178–97.

26. Katzmarzyk PT, Craig CL. Musculoskeletal fitness and risk of mortality. Med Sci Sports Exerc. 2002 May;34(5):740–4.

27. Bokan V. Muscle weakness and other late complications of diabetic polyneuropathy. Acta Clin Croat. 2011 Sep;50(3):351–5.

28. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;(Jul):40.

29. Murphy CH, Saddler NI, Devries MC, McGlory C, Baker SK, Phillips SM. Leucine supplementation enhances integrative myofibrillar protein synthesis in free-living older men consuming lower- and higher-protein diets: a parallel-group crossover study. Am J Clin Nutr. 2016 Dec;104(6):1594–606.

30. Borack MS, Volpi E. Efficacy and Safety of Leucine Supplementation in the Elderly. J Nutr. 2016 Dec;146(12):2625S–9S.

31. Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wast-
ing conditions. J Cachexia Sarcopenia Muscle. 2017 May;8(4):529–41.
32. Jakobsen J, Reske-Nielsen E. Diffuse muscle fiber atrophy in newly diagnosed diabetes. Clin Neuropathol. 1986;5(2):73–7.
33. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type 1 diabetic patients. J Clin Invest. 1995 Jun;95(6):2926–37.
34. Charlton MR, Nair KS. Role of hyperglucagonemia in cachexia associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998 Nov;47(11):1748–56.
35. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest. 1996 Oct;98(4):1703–8.
36. Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, et al. Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. J Physiol. 2013 Jun;591(Pt 11):2911–23.
37. Desikan V, Mileva I, Garlick J, Lane AH, Wilson TA, McNurlan MA. The effect of oral leucine on protein metabolism in adolescents with type 1 diabetes mellitus. Int J Pediatr Endocrinol. 2010;2010:493258.
38. Wędrychowicz A, Dziatkowiak H, Nazim J, Sztefko K, Insulin-Like Growth Factor-1 and Its Binding Proteins, IGF-I, FBP-1 and IGFBP-3, in Adolescents with Type-1 Diabetes mellitus and Microalbuminuria. Horm Res Paediatr. 2005 Jul;63(5):245–51.
39. Sachek JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E591–601.
40. Lowery R, Joy J, Rathmacher J, Baier S, Fuller J, Shelley D, et al. Interaction of Beta-Hydroxy-Beta-Methylbutyrate free acid and adenosine triphosphate on muscle mass, strength, and power in resistance trained individuals. J Strength Cond Res. 2016;30(7):1843–54.
41. Wilson JM, Lowery RP, Joy JM, Andersen JC, Wilson SM, Stout JR, et al. The effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid supplementation on muscle mass, strength, and power in resistance-trained individuals: a randomized, double-blind, placebo-controlled study. Eur J Appl Physiol. 2014 Mar;114(6):1217–27.
42. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol. 1999 May;276(5 Pt 1):C1132–8.
43. van Dam EW, Dekker JM, Lentjes EG, Romijn FP, Smulders YM, Post WJ, et al. Steroids in adult men with type 1 diabetes: a tendency to hypogonadism. Diabetes Care. 2003 Jun;26(6):1812–8.
44. West DW, Kujbida GW, Moore DR, Atherton P, Burd NA, Padzik JP, et al. Resistance exercise-induced increases in putative anabolic hormones do not enhance muscle protein synthesis or intracellular signalling in young men. J Physiol. 2009;587(Pt 21):5239–47.
45. West DW, Burd NA, Tang JE, Moore DR, Staples AW, Holwerda AM, et al. Elevations in ostensibly anabolic hormones with resistance exercise enhance neither training-induced muscle hypertrophy nor strength of the elbow flexors. J Appl Physiol. 2010;108(1):60–7.
46. Cruz B, Oliveira A, Gomes-Marcondes MC. L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine. 2017 Aug;96:253–60.
47. Hoffman JR, Gepner Y, Stout JR, Hoffman MW, Ben-Dov D, Funk S, et al. HMB attenuates the cytokine response during sustained military training. Nutr Res. 2016 Feb;[Ahead of Print]).
48. Zhang L, Pan J, Dong YY, Tweeky DJ, Dong YY, Garibotto G, et al. Stat3 activation links a C/EBP8 to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 2013 Sep;18(3):368–79.
49. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005 Mar;98(3):911–7.
50. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012 Aug;303(3):E410–21.
51. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011 Feb;11(2):98–107.
52. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005 May;45(10):1563–9.
53. Melo LC, Dativo-Medeiros J, Menezes-Silva CE, Barbosa FT, de Sousa-Rodrigues CF, Rabelo LA. Physical Exercise on Inflammatory Markers in Type 2 Diabetes Patients: A Systematic Review of Randomized Controlled Trials. Oxid Med Cell Longev. 2017 Mar;2017:1–10.
54. Costamagna D, Costelli P, Sampaolesi M, Penna F. Role of Inflammation in Muscle Homeostasis and Myogenesis. Mediators Inflamm. 2015;2015:1–14.
55. Inchiostro S, Biolo G, Bruttomesso D, Fongher C, Sabadini L, Carlini M, et al. Effects of insulin and amino acid infusion on leucine and phenylalanine kinetics in type 1 diabetes. Am J Physiol Endocrinol Metab. 1992 Feb;262(2):E203–10.
56. Berard LD, Siemens R, Woo V. Monitoring Glycemic Acid Intakes Are Associated With Bone Mineral Density and Prevalence of Low Bone Mass in Women: Evidence From Discordant Monozygotic Twins. J Bone Miner Res. 2016 Feb;31(2):326–35.
57. Kreider RB, Ferreira M, Wilson M, Almada AL. Effects
of calcium beta-hydroxy-beta-methylbutyrate (HMB) supplementation during resistance-training on markers of catabolism, body composition and strength. Int J Sports Med. 1999 Nov;20(8):503–9.

61. Boonen S, Mohan S, Dequeker J, Aerssens J, Vander-schueren D, Verbeke G, et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res. 1999 Dec;14(12):2150–8.

62. Rieu I, Balage M, Sornet C, Giraudet C, Pujos E, Grizard J, et al. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidemia. J Physiol. 2006 Aug;575(Pt 1):305–15.

63. Bonjour JP. Dietary protein: an essential nutrient for bone health. J Am Coll Nutr. 2005 Dec;24(6 Suppl):S26S–36S.

64. Genaro P S, Martini LA. Effect of protein intake on bone and muscle mass in the elderly. Nutr Rev. 2010 Oct;68(10):616–23.

65. Rizzoli R, Bonjour JP. Dietary Protein and Bone Health. J Bone Miner Res. 2004 Feb;19(4):527–31.

66. Cardoso S, Santos A, Guerra RS, Sousa AS, Padrão P, Moreira P, et al. Association between serum 25-hydroxyvitamin D concentrations and ultraviolet index in Portuguese older adults: a cross-sectional study. BMC Geriatr. 2017 Dec;17(1):256.

67. Chiang C, Ismaeel A, Griffis RB, Weems S. Effects of Vitamin D Supplementation on Muscle Strength in Athletes A Systematic Review. J Strength Cond Res. 2016 Jun;31(2):566–74.

68. Gallagher JC. Vitamin D deficiency and muscle strength: are they related? J Clin Endocrinol Metab. 2012 Dec;97(12):4366–9.

69. Townsend JR, Fragala MS, Jajtner AR, Gonzalez AM, Wells AJ, Mangine GT, et al. β-Hydroxy-β-methylbutyrate (HMB)-free acid attenuates circulating TNF-α and TNFR1 expression postresistance exercise. J Appl Physiol. 2013 Oct;115(8):1173–82.